There's No Best Patient Engagement Platform — Only the Best One for Your Gaps

It's one of the most common questions in patient engagement: what's the best platform?

It has no answer.

Not because the platforms are all the same — they're not — but because "best" is meaningless without the rest of the sentence. Best for what? Best for which gaps, which patients, which points in the journey where your persistence is actually leaking? A platform that's excellent for one team's problem is money wasted for another's. The question as asked can't be answered, because it skips the only thing that would make it answerable: a definition of the problem.

The mistake is buying a solution before defining the problem

Here is how the decision usually goes. A team knows patient persistence is a problem. They start evaluating platforms — demos, feature comparisons, competitor benchmarks, analyst grids. They pick the one that impresses most in the room, or the one a peer company uses, or the one with the strongest sales motion.

And then, often, it doesn't move the numbers. Not because the platform is bad, but because it was aimed at the wrong gap. The team bought a capable solution to a problem it never actually defined — and a solution aimed at the wrong problem is indistinguishable, on the invoice, from a solution that works.

This is the quiet logic that breaks patient engagement investment: we can't solve for what we can't define, and we can't measure what we can't define. A platform is a solution. Selecting one is choosing a solution. But most teams choose the solution before they've defined — specifically, with evidence — what problem it's meant to solve.

Define the problem, and the solution narrows itself. Skip the definition, and no platform can be "best," because there's nothing for "best" to be measured against.

What defining the problem actually looks like

Defining the problem isn't a workshop where everyone agrees persistence matters. It's specific, and it's evidence-based.

It means knowing where in the 90% of the journey your patients are actually falling through — not where you assume, not where the last brand's patients did. It means knowing which of those gaps is costing the most persistence, and therefore the most revenue. And it means knowing which are gaps a platform can close versus gaps that are really cross-functional handoff failures no software will fix.

That last distinction matters more than it sounds. Some of what teams try to solve by buying a platform isn't a platform problem at all — it's a handoff between two functions that don't talk, a coverage gap, an unowned moment in the journey. Buy a platform for that, and you've spent budget without touching the leak. Only a defined problem tells you whether the answer is a platform, a process, a person, or an infrastructure fix — and if it is a platform, which capabilities actually matter for your gaps.

Then the platform question answers itself

Here's what changes once the problem is defined.

The question stops being "what's the best platform?" — a solution question with no answer — and becomes "which platform's capabilities match the specific gaps we've mapped and prioritized?" That question has an answer. You're no longer comparing platforms in the abstract; you're matching capabilities to known needs. The demos become useful, because you know what you're looking for. The benchmarks become relevant, because you know which dimensions matter for your journey. The decision becomes evidence-driven instead of demo-driven.

The platforms haven't changed. What changed is that you defined the problem first, so "best" finally has something to mean.

The instrument for defining the problem

This is the specific job the Gap Finder, our patent-pending diagnostic, was built to do — not to pick your platform, but to define the problem well enough that the platform choice becomes clear.

It maps the patient journey and scores where persistence is actually leaking across the full 90%, with the cross-functional team in the room. It produces a prioritized picture of your specific gaps — which matter most, which are platform-solvable, which are handoff problems no software addresses. What a team walks away with isn't a vendor recommendation. It's a defined problem: here is exactly where we're losing patients, here is what it's costing, here is what a solution would need to do.

With that in hand, the platform decision is no longer a guess. The Gap Finder doesn't make the choice. It makes the choice makeable.

The question worth asking before the next demo

Before your team sits through another platform demo, one question is worth putting on the table:

Have we defined — specifically, with evidence — where our patients are actually falling through? Or are we shopping for a solution to a problem we haven't named?

Because the best platform for the team down the hall may be exactly the wrong one for you. The only way to know is to define your gaps first.

There's no best platform. There's only the best one for the problem you've actually defined.

Linked Patient Learning helps pharma teams define where patient persistence is leaking — so the decision about what to build or buy is driven by evidence, not demos.